Zynerba_Logo-spot_coated_flat_tagline-01.png
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
04 oct. 2023 16h05 HE | Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba_Logo-spot_coated_flat_tagline-01.png
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
29 sept. 2023 09h00 HE | Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba_Logo-spot_coated_flat_tagline-01.png
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
14 sept. 2023 16h15 HE | Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba_Logo-spot_coated_flat_tagline-01.png
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
08 août 2023 16h05 HE | Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for...
Zynerba_Logo-spot_coated_flat_tagline-01.png
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
25 juil. 2023 17h18 HE | Zynerba Pharmaceuticals, Inc.
DEVON, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for...
Zynerba_Logo-spot_coated_flat_tagline-01.png
Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting
28 juin 2023 16h05 HE | Zynerba Pharmaceuticals, Inc.
Annual Meeting Reconvened and Adjourned Without Conducting Business Meeting to Reconvene on July 27, 2023 at 9:00 am EDT DEVON, Pa., June 28, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc....
Zynerba_Logo-spot_coated_flat_tagline-01.png
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
20 juin 2023 07h00 HE | Zynerba Pharmaceuticals, Inc.
DEVON, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba_Logo-spot_coated_flat_tagline-01.png
Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting
13 juin 2023 16h05 HE | Zynerba Pharmaceuticals, Inc.
Meeting adjourned with respect to Proposal 2, Reverse Stock Split; Company encourages additional stockholders of record to vote before reconvened meeting on June 28, 2023 All other proposals...
Zynerba_Logo-spot_coated_flat_tagline-01.png
Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
23 mai 2023 07h00 HE | Zynerba Pharmaceuticals, Inc.
DEVON, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan...
Zynerba_Logo-spot_coated_flat_tagline-01.png
Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights
15 mai 2023 07h00 HE | Zynerba Pharmaceuticals, Inc.
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 $44.4 million in cash and cash...